Baxdela is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Melinta Therapeutics, Llc. The primary component is Delafloxacin Meglumine.
| Product ID | 70842-101_1fbc1d58-acc9-496d-b4b1-898da783df93 |
| NDC | 70842-101 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Baxdela |
| Generic Name | Delafloxacin Meglumine |
| Dosage Form | Tablet |
| Route of Administration | ORAL |
| Marketing Start Date | 2017-06-19 |
| Marketing Category | NDA / NDA |
| Application Number | NDA208610 |
| Labeler Name | Melinta Therapeutics, LLC |
| Substance Name | DELAFLOXACIN MEGLUMINE |
| Active Ingredient Strength | 450 mg/1 |
| Pharm Classes | Fluoroquinolone Antibacterial [EPC],Fluoroquinolones [CS] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2017-06-19 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA208610 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2017-06-19 |
| Marketing Category | NDA |
| Application Number | NDA208610 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2017-06-19 |
| Marketing Category | NDA |
| Application Number | NDA208610 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2019-07-09 |
| Ingredient | Strength |
|---|---|
| DELAFLOXACIN MEGLUMINE | 450 mg/1 |
| SPL SET ID: | fb77637a-88d9-4aea-958f-e270030ce30d |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 70842-101 | Baxdela | delafloxacin meglumine |
| 70842-102 | Baxdela | delafloxacin meglumine |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() BAXDELA 88058147 5725767 Live/Registered |
Melinta Subsidiary Corp. 2018-07-30 |
![]() BAXDELA 86707152 5561401 Live/Registered |
MELINTA SUBSIDIARY CORP. 2015-07-28 |